July 18, 2014
1 min read

Abbott reports positive second-quarter financial results

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Abbott reported a second-quarter ongoing EPS of $0.54, marking a growth of 17.4% above the previous guidance range of $0.50 to $0.52, according to a company press release.

The company also reported diluted EPS of $0.30 from continuing operations under GAAP.

Abbott plans to raise its full-year 2014 ongoing EPS guidance from $2.16 to $2.26 up to $2.19 to $2.29. There is currently a projected full-year 2014 EPS of $1.16 to $1.26 from continuing operations under GAAP, according to the release.

Abbott’s second-quarter worldwide sales increased 3% on an operational basis and 1.9% on a reported basis, which included a 1.1% effect of foreign exchange.

Plans to sell developed markets branded generics pharmaceuticals business to Mylan may positively impact Abbott’s 2015 sales and earnings-per-share growth rates, according to the release.